PharmaCielo Ltd. (PCLOF)


Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In PharmaCielo Ltd. To Contact The Firm 

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (Other OTC:PCLOF) of the May 5, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. 

If you invested in PharmaCielo stock or options between June 21, 2019 and March 2, 2020 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  

The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased PharmaCielo securities between June 21, 2019 and March 2, 2020 (the “Class Period”).  The case, Daniel Gabbard v. PharmaCielo Ltd. et al, No. 20-cv-02182 was filed on March 6, 2020, and has been assigned to Judge Philip S. Gutierrez.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) PharmaCielo engaged in an undisclosed related party transactions with General Extract; (2) PharmaCielo engaged in misleading transactions and loans with General Extract and XPhyto; (3) PharmaCielo’s Research Technology and Processing Centre was never on-schedule and is delayed; (4) the Rionegro facility is located on a floodplain and contaminated with mold and pesticides from its previous tenants; (5) PharmaCielo’s Cauca Department land has never been utilized by the Company and is idle; and (6) as a result , Defendants’ public statements were materially false and/or misleading at all relevant times.

Specifically, on March 2, 2020, Hindenburg Research published a report (the “Report”) explaining that PharmaCielo had failed to disclose: (1) transactions with related parties; (2) misleading business transactions and loans with General Extract and XPhyto; (3) the delayed state of its Research Technology and Processing Centre’s construction; and (4) the poor state of its Rionegro Growing Facility.

On this news, PharmaCielo’s stock fell from a closing price of $1.42 per share over the next two trading days to $0.9068 per share on March 3, 2020— a $0.5132 or 36.14% drop.

 

Contact us

PharmaCielo Ltd. (PCLOF)

Loading captcha, please wait...

* The submission of this form does not create an attorney-client relationship.

Details

Filed on 03/09/2020

Ticker Other OTC:PCLOF

Lead Plaintiff Deadline 05/05/2020

Office

685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331

Counsel

Richard W. Gonnello rgonnello@faruqilaw.com Phone (212) 983-9330 Fax (212) 983-9331

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Delaware

3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania